A prospective, non-randomised, multicenter study on the efficacy and safety of ILUVIEN® in diabetic macular edema patients considered insufficiently responsive to available therapies (REACT).
Latest Information Update: 26 Oct 2016
At a glance
- Drugs Fluocinolone acetonide (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms REACT
- 26 Oct 2016 New trial record